MiNK Therapeutics (INKT) Accumulated Expenses (2020 - 2026)

MiNK Therapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly Accumulated Expenses rose 54.04% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 54.04% YoY) and the FY2025 annual result came in at $1.6 million, down 15.73% from the prior year.
• Accumulated Expenses retreated to $1.3 million in Q1 2026 per INKT's latest filing, from $1.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $5.3 million in Q1 2024 and troughed at $508000.0 in Q2 2022.
• A 5-year average of $2.1 million and a median of $1.6 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 686.77% in 2022, then plunged 83.7% in 2025.
• Over 5 years, Accumulated Expenses stood at $1.7 million in 2022, then jumped by 204.37% to $5.0 million in 2023, then slumped by 62.8% to $1.9 million in 2024, then slipped by 15.73% to $1.6 million in 2025, then retreated by 16.01% to $1.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.3 million, $1.6 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.